查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
全球 PICC（外周插入式中央静脉导管）市场-2022-2029
市场调查报告书
商品编码
1143404

全球 PICC（外周插入式中央静脉导管）市场-2022-2029

Global Peripherally Inserted Central Catheter Market - 2022-2029
出版日期: | 出版商: DataM Intelligence | 英文 200 Pages | 商品交期: 约2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

市场概览

PICC（外周插入中心静脉导管）市场规模预计在预测期间（2022-2029 年）将以 5% 的复合年增长率增长。

PICC（外周插入中央静脉导管）将一根细而柔软的柔性管插入上臂静脉，并将其引导（拧入）心臟右上方的一条大静脉，称为上腔静脉。该静脉输液管允许静脉内给药并有助于采集血液进行测试。

市场动态

医疗保健专业人员使用 PICC 的趋势不断增长，这推动了市场的发展，因为 PICC 与其他导管相比具有优势。由于慢性病增加导致住院人数增加，也增加了 PICC 的使用，推动了全球市场的增长。

医疗保健专业人员对 PICC 的偏好日益增加以及慢性病负担的增加正在推动全球市场的增长。

医疗保健专业人员越来越喜欢 PICC 而非常规 IV 线，这推动了全球市场的增长。由于 PICC 线比常规 IV 更粗、更耐用，因此它们具有几个优点，例如更长的长度和更深地穿透静脉。通过使用 PICC 管路而不是常规 IV 管路，医护人员可以将其放置更长时间（长达 3 个月，有时更长）并减少抽血所需的针刺数量。对于需要静脉注射抗生素数週、静脉营养、需要多次输血的重症感染患者，也是一种非常有效的手段。此外，慢性病负担的增加也在加速 PICC 的使用。例如，世卫组织的数据显示，每年有 4100 万人死于非传染性疾病 (NCD)。预计到 2030 年将增加到 5200 万，占所有死亡人数的 75%（占全球所有死亡人数的 74%），8 年内将有 1700 万人死于非传染性疾病，其中 86% 发生在低收入和中等收入国家。此外，全球非传染性疾病联盟估计，在 2011 年至 2030 年间，仅心血管疾病、呼吸系统疾病、糖尿病和癌症的影响将导致全球累计生产力损失 47 万亿美元。

并发症和缺乏熟练的专业人员正在阻碍全球外周插入中心静脉导管市场的增长。

但是，并发症和相关风险正在限制全球市场的增长。例如，导管会引起感染、深静脉血栓形成 (DVT)、血栓性静脉炎和脱落等问题。此外，线路阻塞迟早会发生。严重的并发症和治疗延误会导致发病率恶化、痛苦增加，有时甚至是致命的后果。此外，缺乏训练有素的专业人员正在阻碍全球市场的增长。例如，插管必须由经过专门培训的专业人员进行，因为存在严重并发症的风险，例如气胸、动脉穿刺、血胸、中风、心律失常和神经损伤。

COVID-19 影响分析

在 COVID-19 期间，ICU 入院人数激增，需要延长中心静脉通路以进行药物插入以及血液样本采集和营养输注。此外，由于 COVID-19 是一种 ARDS，我们能够为需要机械通气的患者增加俯卧位的氧气输送。上肢静脉中的 PICC 是放置在俯卧位患者中难度最低且最可行的中心静脉导管。因此，人保财险在COVID-19疫情期间销量猛增，对疫情期间的市场产生了积极影响。

细分分析

预计在预测期内（2022-2029 年），电力注入 PICC 细分市场需求旺盛。

动力注入 PICC 细分市场主导着全球外周插入中心导管市场，预计在预测期内（2022-2029 年）将保持主导地位。 PICC 适用于重症监护病房，用作所有输液的多用途中心静脉管路，包括高流量输液、血流动力学监测和放射检查期间高压注射造影剂（回顾性研究） .插入是 100% 成功的，并且不会造成重大风险，即使是在患有凝血病的患者中也是如此。此外，感染性和非感染性并发症的发生率极低，维修方便。应用包括高流量输注、高压注射和放射治疗期间的血流动力学监测。

区域分析

预计北美将主导全球外周插入中心静脉导管市场。

北美在全球市场中占有最大份额，预计将在整个预测期内（2022-2029 年）占据主导地位。市场份额大、医院数量多、医疗成本高、老年人口不断增长、癌症、糖尿病和心血管疾病等非传染性疾病病例增加等主要市场参与者的存在，因为它在后台.例如，根据美国医院协会 2022 年统计报告，根据 2020 年财务数据，美国 6,093 家医院，共有 920,531 张床位，2020 年将有 33,356,853 人住院，投资额为 12138.81 亿美元。知道其中涉及成本。根据医疗保险和医疗补助服务中心的数据，到 2020 年，全国医疗保健支出将增长 9.7%，达到 4.1 万亿美元，占国内生产总值 (GDP) 的 19.7%。

此外，随着人口老龄化，非传染性疾病发病率的上升确保了北美在全球市场的主导地位。根据美国国家癌症研究所的数据，2020 年有 1,806,590 名癌症患者被诊断出，606,520 人报告死亡，美国癌症协会估计，2021 年将有超过 190 万人患有癌症。估计有 608,570 人死亡。此外，根据 CDC 的数据，每 34 秒就有一人死于 CVS，到 2020 年 9 月，约有 620 万人将出现心力衰竭，美国有超过 3700 万成年人患有糖尿病，其中五分之一。是糖尿病。人口普查局的 2020 年人口估计显示，超过 5500 万美国人年龄在 65 岁及以上。

竞争格局

全球外周插入式中央静脉导管市场的主要参与者是： AngioDynamics, Inc., Bard Inc., Teleflex Incorporated, B. Braun Melsungen AG, Medtronic plc, Vygon S.A., Cook Medical, Inc., Becton, Dickinson and Company, Boston Scientific Corporation, Argon Medical Devices, Inc. ，Medical Component Inc，Thergenics Corporation。通过产品发布、併购、合作伙伴和联盟等战略，这些市场参与者正在为全球外周插入中心导管市场的增长做出贡献。例如，2022 年 7 月 12 日，Medtronic宣布与 CathWorks 达成共同推广协议，并宣布计划收购它。此外，2022 年 3 月 8 日，Vygon 收购了秘鲁经销商 Macatt Medica。

Medtronic（Plc.

概述

Medtronic plc 是一家总部位于爱尔兰的美国医疗设备製造商。Medtronic成立于 1949 年，总部位于美国明尼苏达州明尼阿波利斯。美敦力经营四项业务：微创治疗组、糖尿病组、恢復性治疗组和心血管组。

产品组合

Medtronic 的外周插入中心静脉导管产品组合包括 Chameleon PTA 球囊导管。

全球外周插入式中央静脉导管市场报告提供对大约 40 多个市场数据表、45 多个图表和估计 200 页的访问。成为。

内容

第一章研究方法与范围

  • 调查方法
  • 调查目的和范围

第 2 章市场定义和概述

第 3 章执行摘要

第 4 章市场动态

  • 市场影响因素
    • 驱动程序
      • 医疗保健医师对 PICC 的偏好日益增加
      • 慢性病负担加重
      • 市场策略
    • 约束因素
      • 缺乏熟练的专业人员
      • 相关并发症
    • 商机
    • 影响分析

第五章行业分析

  • 波特五力分析
  • 供应链分析
  • 监管分析

第 6 章 COVID-19 分析

  • COVID-19 的市场分析
    • COVID-19 之前的市场情景
    • COVID-19 的当前市场情景
    • COVID-19 后或未来情景
  • COVID-19 期间的价格动态
  • 供需范围
  • 大流行期间与市场相关的政府举措
  • 製造商的战略举措
  • 总结

第 7 章按产品类型

  • 动力注入
  • 常规

第 8 章按设计类型

  • 单腔
  • 双腔
  • 多腔

第 9 章，最终用户

  • 医院
  • 门诊手术中心 (ASC)
  • 其他

第 10 章按地区划分

  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 意大利
    • 西班牙
    • 其他欧洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 澳大利亚
    • 其他亚太地区
  • 中东和非洲

第 11 章竞争格局

  • 主要发展和战略
  • 公司份额分析
  • 产品基准

第 12 章公司简介

  • Medtronic, Plc
    • 公司简介
    • 製作产品组合和描述
    • 主要亮点
    • 财务摘要
  • AngioDynamics, Inc.
  • Bard Inc.
  • Teleflex Incorporated
  • B Braun Melsungen AG
  • Vygon S.A
  • Cook Medical, Inc.
  • Becton, Dickinson and Company
  • Boston Scientific Corporation
  • Argon Medical Devices, Inc.
  • Medical Component Inc.
  • Theragenics Corporation（*未详尽列出）

第 13 章数据M

简介目录
Product Code: DMMD61

Market Overview

Peripherally Inserted Central Catheter market size was valued at US$ YY million in 2021 and is estimated to reach US$ YY million by 2029, growing at a CAGR of 5% during the forecast period (2022-2029).

Peripherally Inserted Central Catheter (PICC) is a slim, soft, flexible tube inserted into a vein in the upper arm and guided (threaded) into a large vein above the right side of the heart called the superior vena cava. This intravenous line allows IV medication delivery and facilitates obtaining blood for laboratory testing.

Market Dynamics

The market is pushed by the increasing inclination by healthcare physicians for PICC because of the advantages offered by the PICC compared to other catheters. Also, the growing burden of chronic diseases leads to increased hospitalizations, thereby increasing the use of PICC and fueling the global market growth.

Healthcare physicians' increasing preference for PICC and the growing burden of chronic diseases propel global market growth.

Healthcare physicians' increasing preference for PICC over regular IV lines drives the global market growth. Because it offers a few advantages, such as a thicker and more durable PICC line than a regular IV, it's much more elongated and goes farther into the vein. Health care providers utilize a PICC line instead of a regular IV line because it can remain in place longer (up to 3 months and sometimes a bit more), decreasing the number of needle sticks a child requires for blood draws. Patients can get considerable amounts of fluids or medicines (like chemotherapy) that might not run via standard IVs; it can help someone with a serious infection so they can get IV antibiotics for a few weeks, helps those who need IV nutrition and is also very valuable in case of patients who will need numerous blood transfusions. Furthermore, the increasing burden of chronic diseases also accelerates using PICC. For instance, WHO data signifies that non-communicable diseases (NCDs) kill 41 million people yearly. They are being projected to escalate to 52 million, accounting for 75% of all deaths within just eight years by 2030, equivalent to 74% of all deaths globally; over 17 million people die from an NCD before age 70; 86% of these premature deaths occur in low- and middle-income countries. Furthermore, per the NCD Alliance at the global level, it is estimated that between 2011-2030, the toll of cardiovascular disease, respiratory disease, diabetes and cancer alone could result in a cumulative global loss in productivity of an estimated USD 47 trillion.

The complications and lack of skilled professionals hinder the growth of the global peripherally inserted central catheter market.

However, the complications and associated risks are restraining the global market growth. For instance, the catheters may cause difficulties such as infection, deep venous thrombosis (DVT), thrombophlebitis, and dislodgement. Furthermore, line blockage may occur sooner or later. Severe complications or delayed treatment can lead to increased morbidity, suffering, and occasionally, even a fatal outcome. Furthermore, the lack of trained professionals is hampering the global market growth. For instance, as the placement of these tubes bears a significant risk for serious complications, e.g., pneumothorax, arterial puncture, haemothorax, stroke, arrhythmias and nerve damage, thus must be performed by a specially trained professional.

COVID-19 Impact Analysis

During COVID-19, the ICU admissions were spiked, which required central venous access for longer to draw blood samples and insert medication along with nutritional IVs. Also, as COVID-19 is ARDS, the prone positioning of the patients helped to enhance oxygenation in patients who need a mechanical ventilator. The least challenging and most feasible central venous catheter to place in prone patients is a PICC in an upper extremity vein. Thus, there was a steep rise in PICC sales during the COVID-19 pandemic, which impacted the market positively during the pandemic period.

Segment Analysis

The power-injected PICC segment is predicted to have a high demand during the forecast period (2022-2029).

The power-injected PICC segment dominated the global peripherally inserted central catheters market and is predicted to dominate throughout the forecast period (2022-2029). Because of their advantages in intensive care units such as according to a retrospectively reviewed study, they can be utilized as multipurpose central lines for any infusion, including high-flow infusion, hemodynamic monitoring, and for high-pressure injection of contrast media during radiological processes. Their insertion is successful in 100% of cases and is not associated with substantial risks, even in patients with coagulation disorders. Their upkeep is associated with an extremely low rate of infective and non-infective complications. Applications include high-flow infusions, high-pressure injections and hemodynamic monitoring during radiological procedures.

Geographical Analysis

North America is predicted to command the global peripherally inserted central catheter market.

North America has the largest share in the global market and is expected to dominate throughout the forecast period (2022-2029). Since there is the presence of key market players holding the majority of market share, a large number of hospitals, high healthcare spending, a growing geriatric population, and rising cases of non-communicable diseases like cancer, diabetes, and cardiovascular diseases. For instance, the American Hospital Association statistics 2022 report, financial data from 2020 shows that 6,093 U.S. hospitals with 920,531 total staffed beds had 33,356,853 hospital admission in 2020, causing $1,213,881,001,000 expenses. In addition, according to the Centers for Medicare & Medicaid Services, in 2020, National Health Expenditure grew 9.7% to $4.1 trillion, accounting for 19.7% of Gross Domestic Product (GDP).

Moreover, the growing incidences of non-communicable diseases with the growing geriatric population ensure North America's dominance over the global market. According to National Cancer Institute, in 2020, there were 1,806,590 cancer cases diagnosed and 606,520 cancer deaths reported; American Cancer Society 2021 estimated that over 1.9 million were diagnosed and 608,570 died of cancer. Also, according to the CDC, one person dies every 34 seconds of CVS, and around 6.2 million had heart failure till September 2020; over 37 million U.S. adults with diabetes and 1 out of 5 of them don't know they have it. In addition, over 55 million Americans are 65 or older, per the estimate from the Census Bureau's 2020 population.

Competitive Landscape

The major global peripherally inserted central catheter market players are: AngioDynamics, Inc., Bard Inc., Teleflex Incorporated, B. Braun Melsungen AG, Medtronic plc, Vygon S.A, Cook Medical, Inc., Becton, Dickinson and Company, Boston Scientific Corporation, Argon Medical Devices, Inc., Medical Component Inc., and Theragenics Corporation. Through strategies such as product launches, mergers & acquisitions, partnerships, and collaborations, these market players contribute globally to the growth of the peripherally inserted central catheters market. For instance, in July 12, 2022, Medtronic announced a co-promotion agreement with CathWorks, with an acquisition plan. Also, in March 8, 2022, Vygon acquired Macatt Medica, a Peruvian distribution company.

Medtronic, Plc.

Overview:

Medtronic plc is Ireland based American medical device company. Medtronic was founded in 1949 and is headquartered in Minneapolis, Minnesota, United States. Medtronics deals with four different businesses: the Minimally Invasive Therapies Group, the Diabetes Group, the Restorative Therapies Group, and the Cardiac and Vascular Group.

Product Portfolio:

The Medtronic, Plc product portfolio for peripherally inserted central catheters contains Chameleon PTA Balloon Catheter.

The global peripherally inserted central catheters market report would provide access to approximately 40+ market data tables, 45+ figures, and in the range of 200 (approximate) pages

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increasing Preference for PICC By Healthcare Physicians
      • 4.1.1.2. Growing Burden of Chronic Diseases
      • 4.1.1.3. Market Strategies
    • 4.1.2. Restraints
      • 4.1.2.1. Lack of Skilled Professional
      • 4.1.2.2. Associated Complication
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturer's Strategic Initiatives
  • 6.6. Conclusion

7. By Product Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type Segment
    • 7.1.2. Market Attractiveness Index, By Product Type Segment
  • 7.2. Power Injected
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.3. Conventional

8. By Design Type

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Design Type Segment
    • 8.1.2. Market Attractiveness Index, By Design Type Segment
  • 8.2. Single Lumen
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.3. Double Lumen
  • 8.4. Multiple Lumen

9. By End User

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User Segment
    • 9.1.2. Market Attractiveness Index, By End User Segment
  • 9.2. Hospitals
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 9.3. Ambulatory Surgical Centers (ASCs)
  • 9.4. Others

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Design Type
    • 10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. The U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Design Type
    • 10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. The U.K.
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Design Type
    • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Design Type
    • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Design Type
    • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User

11. Competitive Landscape

  • 11.1. Key Developments and Strategies
  • 11.2. Company Share Analysis
  • 11.3. Product Benchmarking

12. Company Profiles

  • 12.1. Medtronic, Plc
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Key Highlights
    • 12.1.4. Financial Overview
  • 12.2. AngioDynamics, Inc.
  • 12.3. Bard Inc.
  • 12.4. Teleflex Incorporated
  • 12.5. B Braun Melsungen AG
  • 12.6. Vygon S.A
  • 12.7. Cook Medical, Inc.
  • 12.8. Becton, Dickinson and Company
  • 12.9. Boston Scientific Corporation
  • 12.10. Argon Medical Devices, Inc.
  • 12.11. Medical Component Inc.
  • 12.12. Theragenics Corporation(*LIST NOT EXHAUSTIVE)

13. DataM Intelligence

  • 13.1. Appendix
  • 13.2. About Us and Services
  • 13.3. Contact Us